Genprex, Inc. (GNPX) Stock Price, News, Quote & History - Yahoo Finance (2024)

0&&s)if(o){var r,a=(r=e.newCount)>99;s.textContent=a?"99+":r+"",null===(t=s.parentElement)||void 0===t||t.classList.add(zt)}else s.style.display="block"},m=function(){d.refreshPanel().then(h).then(ee).catch((function(){}))};e.addEventListener("close-all-menus",(function(){Le(c)||u()})),c&&(m(),setInterval((function(){m()}),3e5),o?l&&l.addEventListener("mouseenter",(function(){p(),null==t||t.show()})):c.addEventListener("mouseenter",(function(){p(),null==t||t.show()})),c.addEventListener("mouseleave",(function(){u(),null==t||t.hide()}))),e.addElementListener(i,"click",(function(){Q("ybar","notification","",{elm:"btn",elmt:"block"===(null==s?void 0:s.style.display)?"newalert":"",subsec:"notification",itc:"1"})})),r&&Ee(e,r,"ybar","notification",{elm:"expand",subsec:"notifications",itc:"2"}),e.addElementListener(a,"focusin",(function(){i&&(i.checked=!0),null==a||a.classList.add("ybarMenuOpen")})),e.addElementListener(a,"focusout",u),e.addElementListener(n.tooltipContainer,"focusin",(function(){null==t||t.show()})),e.addElementListener(n.tooltipContainer,"focusout",(function(){null==t||t.hide()}));var f=e.getConfig().device,v=document.getElementById("ybar");v&&v.classList.contains("ybar-ytheme-crunch")&&(eo=0);var y=new RegExp("[?&]notifications=1(&|#|$)");"desktop"===f&&i&&y.test(window.location.search)&&(i.checked=!0)};ye("ybar-mod-notification",(function(e){var n={isUH3:"crunch"===e.getConfig().ytheme,notifContainer:document.getElementById("notification-container"),notifBadge:document.getElementById("notif-badge"),notifMenu:document.getElementById("ybarNotificationMenu"),notifMenuOpener:document.querySelector("#ybarNotificationMenu + label"),notifDropdown:document.getElementById("notifDropdownContainer"),tooltipContainer:document.querySelector(".".concat(Gt)),notifLabel:document.querySelector(".".concat(Wt))};to(e,n)}))}()}};

NasdaqCM - Delayed Quote • USD

Compare

1.4100 -0.1000 (-6.62%)

At close: August 6 at 4:00 PM EDT

1.4000 -0.01 (-0.71%)

After hours: August 6 at 7:37 PM EDT

Key Events

Line

Candle

Baseline

Mountain

Bar

Advanced Chart

Loading Chart for GNPX

9/21 12:03 PM

DELL

Date
Close
Open
High
Low
Volume

• Previous Close 1.5100
• Open 1.4550
• Bid --
• Ask --
• Day's Range 1.4100 - 1.4996
• 52 Week Range 1.4100 - 28.8400
• Volume 25,802
• Avg. Volume 103,362
• Market Cap (intraday) 2.959M
• Beta (5Y Monthly) -0.51
• PE Ratio (TTM) --
• EPS (TTM) -18.8100
• Earnings Date Aug 21, 2024 - Aug 26, 2024
• Forward Dividend & Yield --
• Ex-Dividend Date --
• 1y Target Est 165.00

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

www.genprex.com

26

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

More about Genprex, Inc.

Recent News: GNPX

View More

All SEC Filings

Corporate Changes & Voting Matters

Periodic Financial Reports

Proxy Statements

Tender Offer/Acquisition Reports

Offering Registrations

See Also

Genprex Inc (GNPX) Stock Message Board | InvestorsHubGenprex Inc (GNPX) Stock Price & News - Google FinanceGenprex, Inc. (GNPX) Stock Price, Quote & News - Stock AnalysisGenprex, Inc. (GNPX) Latest Stock News & Headlines - Yahoo Finance

View More

Performance Overview: GNPX

Trailing total returns as of 8/6/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

GNPX

84.67%

S&P 500

9.86%

1-Year Return

GNPX

95.08%

S&P 500

17.02%

3-Year Return

GNPX

98.82%

S&P 500

18.31%

5-Year Return

GNPX

96.25%

S&P 500

84.20%

Compare To: GNPX

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

GNPXGenprex, Inc.

1.4100

-6.62%

Mkt Cap 2.959M

Industry Biotechnology

RVPHReviva Pharmaceuticals Holdings, Inc.

0.9001

-4.80%

Mkt Cap 26.839M

Industry Biotechnology

CINGCingulate Inc.

0.3080

+4.41%

Mkt Cap 3.221M

Industry Biotechnology

CRDFCardiff Oncology, Inc.

2.2400

+8.47%

Mkt Cap 100.211M

Industry Biotechnology

MISTMilestone Pharmaceuticals Inc.

1.3400

+3.08%

Mkt Cap 71.381M

Industry Biotechnology

SNSESensei Biotherapeutics, Inc.

0.6500

+6.56%

See Also

GNPX Stock Price and Chart — NASDAQ:GNPX — TradingView

Mkt Cap 16.303M

Industry Biotechnology

ADTXAditxt, Inc.

0.9970

+10.04%

Mkt Cap 1.988M

Industry Biotechnology

EQEquillium, Inc.

0.7299

+15.22%

Mkt Cap 25.732M

Industry Biotechnology

ZVSAZyVersa Therapeutics, Inc.

3.3700

+3.69%

Mkt Cap 2.814M

Industry Biotechnology

CYDYCytoDyn Inc.

0.1299

-0.84%

Mkt Cap 137.507M

Industry Biotechnology

ELEVElevation Oncology, Inc.

0.7802

-63.37%

Mkt Cap 42.629M

Industry Biotechnology

Statistics: GNPX

View More

Valuation Measures

Annual

As of 8/5/2024

• Market Cap

  3.09M

• Enterprise Value

  -5.13M

• Trailing P/E

  --

• Forward P/E

  --

• PEG Ratio (5yr expected)

  --

• Price/Sales (ttm)

  --

• Price/Book (mrq)

  0.35

• Enterprise Value/Revenue

  --

• Enterprise Value/EBITDA

  0.18

Financial Highlights

Profitability and Income Statement

• Profit Margin

  0.00%

• Return on Assets (ttm)

  -96.86%

• Return on Equity (ttm)

  -202.83%

• Revenue (ttm)

  --

• Net Income Avi to Common (ttm)

  -27.63M

• Diluted EPS (ttm)

  -18.8100

Balance Sheet and Cash Flow

• Total Cash (mrq)

  8.22M

• Total Debt/Equity (mrq)

  --

• Levered Free Cash Flow (ttm)

  -13.02M

View More

Research Analysis: GNPX

View More

View More

Company Insights: GNPX

Research Reports: GNPX

View More

View More

People Also Watch

DARE Daré Bioscience, Inc.

3.2200

+0.31%

CODX Co-Diagnostics, Inc.

1.1100

+5.71%

COCP Cocrystal Pharma, Inc.

1.7500

0.00%

AIM AIM ImmunoTech Inc.

0.3235

+0.28%

AYTU Aytu BioPharma, Inc.

2.4500

+0.41%

OPGN OpGen, Inc.

2.2700

-11.33%

VTVT vTv Therapeutics Inc.

14.66

+0.90%

AGRX Agile Therapeutics, Inc.

1.4600

0.00%

NNVC NanoViricides, Inc.

2.0600

+1.98%

CTXR Citius Pharmaceuticals, Inc.

1.0200

+9.40%

PIXY ShiftPixy, Inc.

1.1500

-4.96%

CAPR Capricor Therapeutics, Inc.

3.9100

+3.71%

CLSD Clearside Biomedical, Inc.

1.0900

0.00%

HOTH Hoth Therapeutics, Inc.

0.6280

-0.81%

BSGM BioSig Technologies, Inc.

0.3500

+5.42%

VBIV VBI Vaccines Inc.

0.1329

+111.29%